ATLANTA, GA--(Marketwire - March 04, 2008) - MIV Therapeutics, Inc. (OTCBB: MIVT) (FRANKFURT: MIV), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced changes to its Scientific Advisory Board and Clinical Advisory Group.
